We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

133 hedge funds and large institutions have $385M invested in Progenics Pharmaceuticals Inc in 2015 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 43 increasing their positions, 43 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 12

29% more call options, than puts

Call options by funds: $1.14M | Put options by funds: $886K

10% more funds holding

Funds holding: 121133 (+12)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 43

23% less capital invested

Capital invested by funds: $501M → $385M (-$116M)

Holders
133
Holders Change
+12
Holders Change %
+9.92%
% of All Funds
3.71%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
24
Increased
43
Reduced
43
Closed
12
Calls
$1.14M
Puts
$886K
Net Calls
+$254K
Net Calls Change
-$1.04M
Name Holding Trade Value Shares
Change
Change in
Stake
OAM
26
Oxford Asset Management
United Kingdom
$2.19M -$6M -781,581 -67%
PCM
27
Piermont Capital Management
Missouri
$2.08M +$98.6K +12,855 +4%
Invesco
28
Invesco
Georgia
$1.91M +$2.55M +332,555 +46,839%
Acadian Asset Management
29
Acadian Asset Management
Massachusetts
$1.83M +$2.43M +316,841 +8,885%
BA
30
BKS Advisors
Michigan
$1.67M
TI
31
Turner Investments
Pennsylvania
$1.45M
TCIM
32
TIAA CREF Investment Management
New York
$1.43M +$66.1K +8,609 +4%
CAM
33
CG Asset Management
New York
$1.4M +$1.88M +244,400 New
BIM
34
BlackRock Investment Management
Delaware
$1.4M -$22.3K -2,900 -1%
Ameriprise
35
Ameriprise
Minnesota
$1.38M -$197K -25,637 -10%
California Public Employees Retirement System
36
California Public Employees Retirement System
California
$1.26M
RFC
37
Russell Frank Company
Washington
$1.17M -$482K -62,783 -23%
PAM
38
Panagora Asset Management
Massachusetts
$1.08M +$338K +44,049 +30%
Goldman Sachs
39
Goldman Sachs
New York
$1.05M +$157K +20,457 +13%
SGAM
40
Smith Group Asset Management
Texas
$893K +$1.2M +156,060 New
CCM
41
Cadence Capital Management
Massachusetts
$853K -$111K -14,507 -9%
New York State Common Retirement Fund
42
New York State Common Retirement Fund
New York
$838K +$235K +30,634 +26%
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$725K -$3.07K -400 -0.3%
Susquehanna International Group
44
Susquehanna International Group
Pennsylvania
$677K -$916K -119,434 -50%
BA
45
BlackRock Advisors
Delaware
$624K -$22.9K -2,981 -3%
Charles Schwab
46
Charles Schwab
California
$607K -$1.33M -173,664 -62%
AllianceBernstein
47
AllianceBernstein
Tennessee
$582K
TA
48
Teachers Advisors
New York
$582K
SO
49
STRS Ohio
Ohio
$571K +$767K +99,947 New
AIG
50
American International Group
New York
$556K -$227K -29,594 -23%

PGNX Hedge Fund Activity: Q3 2015 in Review

133 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q3 2015, worth a combined $385M — down 23% from $501M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new PGNX positions and 12 closed out — a net gain of 12 holders — while 43 added to existing stakes and 43 trimmed.

The largest buyer was Bogle Investment Management, opening a new position worth an estimated $6.06M. The largest seller was Wellington Management Group, cutting an estimated $6.12M.

  • 133 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q3 2015, up from 121 in Q2 2015.
  • Funds reported $385M of Progenics Pharmaceuticals Inc stock for Q3 2015, down 23% quarter-over-quarter.
  • 24 funds opened new Progenics Pharmaceuticals Inc positions in Q3 2015 and 12 closed out, a net change of +12 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q3 2015 was Bogle Investment Management, an estimated $6.06M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q3 2015 was Wellington Management Group, an estimated $6.12M sold.

Based on aggregated 13F filings for Q3 2015.